论文部分内容阅读
长期以来,国内外学者对于华法林在老年心房颤动患者的卒中一级预防中的疗效及安全性一直存在争议。在2007年8月11日出版的LANCET杂志上,BAFTA(Birmingham Atrial Fibrillation Treatment of the Aged,伯明翰老年房颤患者的治疗)试验的初步结果揭晓,该研究表明,华法林在老年房颤患者卒中一级预防中的作用优于阿司匹林,且不增加严重出血性疾病的危险性。BAFTA试验主要研究者之一Mant教授指出,华法林可以安全有效的用于无禁忌证的75岁以上的老年房颤患者,其INR目标值同样为2～3,高龄本身不是抗凝治疗的禁忌证。此研究结果对于老年房颤患者的治疗具有重要指导意义。
For a long time, domestic and foreign scholars have been controversial about the efficacy and safety of warfarin in primary prevention of stroke in elderly patients with atrial fibrillation. Preliminary results of the BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged trial) trial in LANCET, August 11, 2007, revealed that warfarin was effective in stroke in elderly patients with atrial fibrillation The role of primary prevention is better than aspirin, and does not increase the risk of serious bleeding disorders. Professor Mant, one of the BAFTA trial lead investigators, pointed out that warfarin can safely and effectively be used in non-contraindications for AF in elderly patients over 75 years of age with a target INR of 2 to 3, with advanced age itself not anticoagulant Contraindications. The results of this study for the treatment of elderly patients with atrial fibrillation has important guiding significance.